Dapagliflozin Reduces Hospitalizations Among Patients With CKD

TUESDAY, Dec. 6, 2022 -- For patients with chronic kidney disease (CKD), dapagliflozin reduces the risk for hospitalization, according to a study published online Dec. 6 in the Annals of Internal Medicine. Meir Schechter, M.D., from the University...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news